Short answer
Merck’s biggest product is Keytruda, a cancer immunotherapy that generates the highest sales for the company and has become a standard of care for several cancers.
Key points
- Keytruda leads Merck’s revenue and clinical impact.
- Gardasil remains a major preventive vaccine for HPV.
- Januvia and Janumet continue to be key diabetes treatments.
- Keytruda’s approval expanded treatment options for melanoma and lung cancer.
- Merck’s portfolio balances oncology, vaccines, and metabolic drugs.
Merck’s biggest product is Keytruda, a cancer immunotherapy that has become the company’s top seller and a cornerstone of modern oncology.
Keytruda’s impact
Approved for multiple cancer types—including melanoma, non‑small cell lung cancer, and others—Keytruda works by activating the immune system to target tumor cells. Its high sales reflect widespread adoption by oncologists and patients seeking alternatives to traditional chemotherapy.
Other major products
While Keytruda dominates revenue, Merck also markets Gardasil, a vaccine that protects against human papillomavirus and reduces cervical cancer risk, and Januvia/Janumet, widely prescribed diabetes medications that help manage blood sugar levels. These products demonstrate Merck’s strength in both therapeutic and preventive medicine.
Frequently asked questions
What cancers can Keytruda treat?
Keytruda is approved for melanoma, non‑small cell lung cancer, head and neck squamous cell carcinoma, bladder cancer, and several others, depending on patient biomarkers.
How does Keytruda differ from other immunotherapies?
Keytruda blocks the PD‑1 pathway, enhancing T‑cell activity against tumors, while other immunotherapies may target different checkpoints or use checkpoint inhibitors in combination.
What is the role of Gardasil?
Gardasil protects against high‑risk HPV strains that cause cervical, anal, and other cancers, and it is a key component of global vaccination programs.
Comments
No comments yet. Be the first to react.